HealthCap
HealthCap
  • About
    • Our Story
    • Strategy
    • ESG Policy
    • Partners
    • Team
    • Special Advisors
  • 1996 – 2021
  • Investments
    • Portfolio Companies
    • Approved Products
  • News
    • Portfolio Companies
    • HealthCap
  • Contact & Legal
    • Contact Us
    • Privacy Policy
    • Cookie Policy
  • LinkedIn
  • Wikipedia
HealthCap

HealthCap is a family of venture capital funds investing globally in life sciences. With more than EUR 1.2 billion raised since the start in 1996, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

Read more

Portfolio Companies News

  • March 29, 2023
    Vicore receives Innovation Passport...

    Stockholm, March 29, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2-receptor agonists (ATRAGs), today announces that the UK MHRA (Medicines and Healthcare products Regulatory Agency) has awarded Vicore Innovation Pa... read more

  • March 28, 2023
    Oncopeptides receives a research gr...

    March 28, 2023 Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company has received a research grant of 3 MSEK from Sweden´s Innovation... read more

  • March 20, 2023
    Fusion Pharmaceuticals Announces Fi...

    HAMILTON, ON and BOSTON, March 20, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first patient has been dosed in ... read more

  • March 16, 2023
    Spruce Biosciences Reports Full Yea...

    CAHmelia-203 in Adult Classic CAH Surpasses 50% Enrollment Private Placement Financing of $53.6 million in Gross Proceeds with Top-Tier Healthcare Investors Strategic Partnership and Exclusive Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Tilda... read more

  • March 16, 2023
    Fusion Pharmaceuticals Announces Fo...

    Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC FPI-1434 preliminary Phase 1 data expected in Q2 2023 FPI-1966 and FPI-2059 Phase 1 trials open and recruiting patients St... read more

HealthCap Info

  • February 21, 2023
    Q4 2022 General Market Overview
  • March 06, 2023
    Artikel i Life Science Sweden
  • November 29, 2021
    HealthCap’s 25th company anniversary!

Facts

  • 126

    Since the start in 1996, HealthCap funds have invested in 126 portfolio companies.

    Read more
  • 47

    47 of the portfolio companies have been taken public on fourteen different markets.

    Read more
  • 31

    31 of the portfolio companies pharmaceutical products have been approved for marketing.

    Read more
  • 12

    Unicorn Factory
    Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.

    Read more

Our story

HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative...

Read more

Subscribe to news

Venture Capital for Breakthrough Therapies

This site uses cookies. But first we need your consent. More info.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close